

## Table of Contents

State/Territory Name: Louisiana

State Plan Amendment (SPA) #: 15-0022 NIRT

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form
- 3) Approved SPA Page

DEPARTMENT OF HEALTH & HUMAN SERVICES  
Centers for Medicare & Medicaid Services  
7500 Security Boulevard, Mail Stop S3-14-28  
Baltimore, Maryland 21244-1850



---

**Financial Management Group**

OCT 14 2015

Ms. Ruth Kennedy, Director  
Bureau of Health Services Financing  
Department of Health and Hospitals  
Post Office Box 91030  
Baton Rouge, Louisiana 70821-9030

RE: Louisiana 15-0022

Dear Ms. Kennedy:


We have reviewed the proposed State plan amendment (SPA) to Attachment 4.19-A of your Medicaid State plan submitted under transmittal number (TN) 15-0022. Louisiana Department of Health and Hospitals submitted this SPA to amend the inpatient hospital methodology to reinstate the additional reimbursement for hemophilia blood products purchased by non-rural non-state acute care hospitals.

We conducted our review of your submittal according to the statutory requirements at sections 1902(a)(2), 1902(a)(13), 1902(a)(30), 1903(a), and 1923 of the Social Security Act and the implementing Federal regulations at 42 CFR 447 Subpart C. As part of the review process the State was asked to provide information regarding funding of the State share of expenditures under Attachment 4.19-A.

Based upon the information provided by the State, Medicaid State plan amendment 15-0022 is approved effective July 1, 2015. We are enclosing the CMS-179 and the new plan page.

If you have any questions, please call Tamara Sampson at (214) 767-6431.

Sincerely,



Timothy Hill  
Director

A handwritten signature in black ink, appearing to be "T. Hill", written over the printed name and title.

Enclosures

<b>TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL</b>  <b>FOR: HEALTH CARE FINANCING ADMINISTRATION</b>		1. TRANSMITTAL NUMBER:  <div style="text-align: center;"><b>15-0022</b></div>	2. STATE  <div style="text-align: center;"><b>Louisiana</b></div>
TO: REGIONAL ADMINISTRATOR HEALTH CARE FINANCING ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES		3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT (MEDICAID)	
5. TYPE OF PLAN MATERIAL (Check One):  <input type="checkbox"/> NEW STATE PLAN <input type="checkbox"/> AMENDMENT TO BE CONSIDERED AS NEW PLAN <input checked="" type="checkbox"/> AMENDMENT COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AMENDMENT (Separate Transmittal for each amendment)		4. PROPOSED EFFECTIVE DATE  <div style="text-align: center;"><b>July 1, 2015</b></div>	
6. FEDERAL STATUTE/REGULATION CITATION: <b>42 CFR 447, Subpart C</b>	7. FEDERAL BUDGET IMPACT: a. FFY <u>2016</u> <span style="float: right;"><b>\$ 46.54</b></span> b. FFY <u>2017</u> <span style="float: right;"><b>\$188.03</b></span>		
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:  <b>Attachment 4.19-A, Item 1, Page 8d</b>	9. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable):  <b>Same (TN 15-0013)</b>		
10. SUBJECT OF AMENDMENT: <b>The purpose of this SPA is to amend the provisions governing the reimbursement methodology for inpatient hospital services rendered by non-rural, non-state hospitals to reinstate reimbursements for costs incurred in the purchase of blood products for certain Medicaid recipients diagnosed with, and receiving inpatient treatment for, hemophilia.</b>			
11. GOVERNOR'S REVIEW (Check One): <input type="checkbox"/> GOVERNOR'S OFFICE REPORTED NO COMMENT <input checked="" type="checkbox"/> OTHER, AS SPECIFIED: <input type="checkbox"/> COMMENTS OF GOVERNOR'S OFFICE ENCLOSED <b>The Governor does not review state plan material.</b> <input type="checkbox"/> NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL			
12. SIGNATURE OF AGENCY OFFICIAL: <div style="background-color: black; width: 100px; height: 30px; margin-top: 5px;"></div>	16. RETURN TO:  <b>J. Ruth Kennedy, Medicaid Director</b> <b>State of Louisiana</b> <b>Department of Health and Hospitals</b> <b>628 N. 4<sup>th</sup> Street</b> <b>P.O. Box 91030</b> <b>Baton Rouge, LA 70821-9030</b>		
13. TYPED NAME: <b>Kathy H. Kliebert</b>	15. DATE SUBMITTED: <b>July 31, 2015</b>		
14. TITLE: <b>Secretary</b>			
<b>FOR REGIONAL OFFICE USE ONLY</b>			
17. DATE RECEIVED: <b>8-5-2015</b>	18. DATE APPROVED: <b>OCT 14 2015</b>		
<b>PLAN APPROVED – ONE COPY ATTACHED</b>			
19. EFFECTIVE DATE OF APPROVED MATERIAL: <b>7-1-2015</b>	20. SIGNATURE OF REGIONAL OFFICIAL: <div style="background-color: black; width: 100px; height: 30px; margin-top: 5px;"></div>		
21. TYPED NAME: <b>Kristin FAW</b>	22. TITLE: <b>Deputy Director, FMC</b>		
23. REMARKS:			

STATE OF LOUISIANA  
PAYMENT FOR MEDICAL AND REMEDIAL CARE AND SERVICES

---

METHODS AND STANDARDS FOR ESTABLISHING PAYMENT RATES - INPATIENT HOSPITAL CARE

---

10. Additional Payments for Non-Rural, Non-State Hospitals

**Hemophilia Blood Products**

Effective for dates of service on or after July 1, 2015, the Department of Health and Hospitals shall provide additional reimbursements to certain non-rural, non-state acute care hospitals for the extraordinary costs incurred in purchasing blood products for certain Medicaid recipients diagnosed with, and receiving inpatient treatment for hemophilia.

A. Hospital Qualifications

To qualify for the additional reimbursement, the hospital must:

1. be classified as a major teaching hospital and contractually affiliated with a university located in Louisiana that is recognized by the Centers for Disease Control and Prevention and the Health Resource and Services Administration, Maternal and Child Health Bureau as maintaining a comprehensive hemophilia care center;
2. have provided clotting factors to a Medicaid recipient who:
  - a. has been diagnosed with hemophilia or other rare bleeding disorders for which the use of one or more clotting factors is Food and Drug Administration (FDA) approved; and
  - b. has been hospitalized at the qualifying hospital for a period exceeding six days; and
3. have actual cost exceeding \$50,000 for acquiring the blood products used in the provision of clotting factors during the hospitalization.
  - a. Actual cost is the hospital's cost of acquiring blood products for the approved inpatient hospital dates of service as contained on the hospital's original invoices, less all discount and rebate programs applicable to the invoiced products.

B. Reimbursement

Hospitals who meet the above qualifications may receive reimbursement for their actual costs that exceed \$50,000 if the hospital submits a request for reimbursement to the Medicaid Program within 180 days of the patient's discharge from the hospital.

The request for reimbursement shall be submitted in a format specified by the Department.

---

TN 15-0022

Approval Date OCT 14 2015

Effective Date 7-1-2015

Supersedes

TN 15-0013

State: Louisiana
Date Received: August 5, 2015
Date Approved: OCT 14 2015
Date Effective: July 1, 2015
Transmittal Number: 15-0022